Advertisement

Urological Research

, Volume 16, Issue 5, pp 363–366 | Cite as

Effects of cimetidine, progesterone, cannitracin and tolazoline on the weight and DNA content of the testosterone-induced hyperplastic prostate of the rat

  • W. Chen
  • X. M. Zhou
  • D. Y. Chen
  • J. S. Kang
Original Articles

Summary

The antiandrogenic potency of cimetidine, progesterone, cannitracin and tolazoline was studied in intact immature rats by determination of the weight and DNA content of the ventral prostate. Cimetidine is a H-2-recepter histamine antagonist, cannitracin is an antifungal antibiotic derived from Strp.griseus and tolazoline is an α-adrenergic blocker similar to phentolamine. All rats (except the control group) received testosterone propionate (TP) 0.3 mg s.c. with the drugs above every day for one week. Cimetidine, progesterone and cannitracin, but not tolazoline, significantly decreased the weight and DNA content of the hyperplastic prostate induced by TP. The results indicate that cimetidine, progesterone and cannitracin have an antiandrogenic effect. This study provides the basis for investigating the effects of antiandrogen in men with symptomatic benign prostatic hyperplasia.

Key words

Cimetidine Progesterone Cannitracin Tolazoline Benign prostatic hyperplasia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Caine M, Perlberg S, Gordon R (1975) The treatment of benign prostatic hypertrophy with flutamide (Sch 1351). A placebo controlled study. J Urol 114:564–568Google Scholar
  2. 2.
    Bruchovsky N, Wilson JD (1968) The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 243:2012–2021Google Scholar
  3. 3.
    Meikle AW, Collier ES, Middleton RG, Fang SM (1980) Supranormal nuclear content of 5α-dihydrotestosterone in benign hyperplastic prostate of humans. J Clin Endocrinol Metab 51:945–947Google Scholar
  4. 4.
    Tang JR (1985) Cimetidine in the treatment of prostatic hyperplasia (report of 17 cases) Sichuan Med J 6:345Google Scholar
  5. 5.
    Paulson DF, Kane RF (1975) Medrogestone: A prospective study in the pharmaceutical management of benign prostatic hyperplasia. J Urol 113:811–815Google Scholar
  6. 6.
    Wolf H, Madsen PO (1968) Treatment of benign prostatic hypertrophy with progestational agents: A preliminary report. J Urol 99:780–785Google Scholar
  7. 7.
    Abrams PH (1977) A double-blind trial of the effects of candicidin on patients with benign prostatic hypertrophy. Br J Urol 49:67–71Google Scholar
  8. 8.
    Jensen MK, Madsen PO (1983) candicidin treatment of protatism. Urol Res 11:7–10Google Scholar
  9. 9.
    Shen ZG, Shi SF (1981) The therapeutic effect of cannitracin on benign prostatic hyperplasia. Zhejiang Med J 3:27–28Google Scholar
  10. 10.
    Chang DY, Pun BL, Gou YL (1984) The therapeutic effect of cannitracin on BPH. Chin J Urol 5:168–169Google Scholar
  11. 11.
    Coffey DS, Shimazaki JUN, William-Ashman HG (1968) Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch Biochem Biophys 124:184–198Google Scholar
  12. 12.
    Sufrin G, Coffey DS (1973) A new model for studying the effect of drugs on prostatic growth. I. Antiandrogens and DNA synthesis. Invest Urol 11:45–54Google Scholar
  13. 13.
    DeKlerk DP, Coffey DS (1978) Quantitative determination of prostatic epithelial and stromal hyperplasia by a new technique biomorphmetrics. Invest Urol 16:240–245Google Scholar
  14. 14.
    Scott WW, Wade JC (1969) Medical treatment of benign modular prostatic hyperpasia with cyproterone acetate. J Urol 101:81–85Google Scholar
  15. 15.
    Geller J, Bora R, Roberts T, Newman H, Lin A, Silva R (1965) Treatment of benign prostatic hypertrophy with hydroxy progesterone caproate: Effect on clinical symptoms, morphology and endocrine function. JAMA 193:121–128Google Scholar
  16. 16.
    Tesar C, Scott WW (1964) A search for inhibitors of prostatic growth stimulators. Invest Urol 1:482–489Google Scholar
  17. 17.
    Dorfman RI (1971) Antiandrogens. In: James V, Martini L (eds) Proceedings of the 3rd International Congress on Hormonal Steroids. Excerpta medica, Amsterdam, p 995Google Scholar
  18. 18.
    Hall WH (1976) Breast changes in males on cimetidine. N Eng J Med 295:841Google Scholar
  19. 19.
    Sharpe PC, Hawkins BW (1977) Efficacy and safety of cimetidine: Long term treatment with cimetidine. In: Burland WL, Simpkins MA (eds) Cimetidine. Proceedings of the 2nd International Symposium on Histamine H-2-Receptor Antagonists. Excerpta medica, Amsterdam, p 358Google Scholar
  20. 20.
    Leslis GB, Walker TF (1977) A toxicological profile of cimetidine. In: Burland WL, Simpkins MA (eds) Cimetidine. Proceedings of the 2nd International Symposium on Histamine H-2-Receptor Antagonists. Excerpta medica, Amsterdam, p 24Google Scholar
  21. 21.
    Elton RL, Edgren RA (1958) Biological action of 17α-(2-methallyl)-19-nortestosterone, an orally active progestational agent. Endocrinology 63:464–472Google Scholar
  22. 22.
    Woodruff MW, Umiker WO (1960) The effect of estrogen and androgen on the rat prostate gland and testes. J Urol 84:162–166Google Scholar
  23. 23.
    Gordon HW, Schaffner CP (1968) The effect of polyene macrolides on the prostate gland and canine prostatic hyperplasia. Proc Natl Acad Sci USA 60:1201–1208Google Scholar
  24. 24.
    Kwon IH, Fisher H (1972) Effect of candicidin on plasma cholesterol of the adult chicken. Fed Proc 31:728Google Scholar
  25. 25.
    Raz S, Zeigler M, Caine M (1973) Pharmacological receptors in the prostate. Br J Urol 45:663–667Google Scholar
  26. 26.
    Caine M, Raz S, Zeigler M (1975) Adrenergic and cholinergic receptors in human prostate, prostatic capsule and bladder neck. Br J Urol 47:193–202Google Scholar
  27. 27.
    Caine M (1986) The present role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. J Urol 136: 1–4Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • W. Chen
    • 1
  • X. M. Zhou
    • 1
  • D. Y. Chen
    • 1
  • J. S. Kang
    • 1
  1. 1.Department of Urologic SurgeryNanjing Railway Medical CollegeNanjingPeople's Republic of China

Personalised recommendations